News archive
EASD 2024 – MADRID [SEPTEMBER 9-13]
PILA PHARMA will participate in the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD) of Diabetes. The company is excited to meet with peers in the metabolic space to learn about the newest scientific developments and discuss how PILA PHARMA’s unique and potential first-in-class TRPV1-antagonist could offer a beneficial new drug for patients.
PILA PHARMA will be represented by Founder, Chairman & CSO Dorte X. Gram as well as CEO Gustav H. Gram
Thursday August 29: Redeye Investor Forum [ONLINE] 14:00 CET
CEO Gustav H. Gram will present the company and its half year report and give introduction to its unique treatment for obesity & type 2 diabetes, the market and the overall investment case
Wednesday August 28: Aktiespararna Life Science Day [ONLINE] 20:00 CET
CEO Gustav H. Gram will present the company and its unique treatment for obesity & type 2 diabetes
June 27th-30th, 2024
PILA PHARMA will present the hypothesis of targeting the “chili-receptor”, TRPV1 in metabolic disorders.
BIO International Convention
San Diego, US: Monday to Thursday, 3-6 June 2024
Thursday May 22
Redeye Theme: Diabetes
Online: Thursday 24 May 2024 at 9:30 CET
Wednesday April 17
Aktiespararna Lifescience Day [Online] 15:45 CET
Presentation with ‘Aktiespararna’ at their annual Lifescience Day on the outlook of Pila Pharma in a global diabetes and obesity context.
Dansk Aktionærforening Fyn [INVESTOR DAGEN] (Odense, Denmark)
Tuesday, 16 April 2024 from 15:00 CET
Redeye Online Investor Event (ONLINE / Stockholm, Sweden)
Thursday, 11 April 2024 from 14:00 CET
Dansk Aktionærforening Vestegnen (Vallensbæk, Denmark)
Hør Pila Pharma fortælle om deres historie og projekter inden for diabetes og fedmemedicin hos Dansk Aktionærforening på Vestegnen.
(26 March-2024)
AktieInfo Danmark – Sydhavnen (Copenhagen S, Denmark)
(21 March-2024)
Business conference to meet with Swiss investors and engage in partnership discussions with Swiss pharma companies.
Swiss-Nordic BIO (Zürich, Switzerland)
(7 March-2024)
Mød stifter og CEO, Dorte X. Gram, der fortæller om den spæde start som PhD på Novo Nordisk hvor opfindelsen fandt sted, de lovende studier og planerne for 2024.
Dansk Aktionærforening Trekant (Kolding, Denmark)
(4 March-2024)
Earnings call with comments on 2023, and outlook on 2024 with CEO Dorte X. Gram
Submit questions beforehand and sign up via this link. Stokk.io (ONLINE EVENT)
(28 February-2024)
Our CEO Dorte X Gram will be attending the Nordic Life Science Days 2023.
Nordic Life Science will be held for the first time and for its 10th anniversary in Copenhagen, Denmark at Bella Arena
(20 Nov-2023)
CEO Dorte X. Gram presenting PILA PHARMA’s diabete drug project for the treatment of type 2 diabetes at the Diabetes Event hosted by Redeye.
Please, find the link to the video (in English) here
(26 May-2023)
CEO Dorte X. Gram presenting PILA PHARMA’s new orphan drug project for the treatment of rare disease Erythromelalgia at the Orphan Drugs day hosted by Redeye.
Please, find the link to the video (in English) here
Happy to have been featured with the frontpage and a good article this week in the special section “Hälsa & Forskning” from Swedish newspaper Svenska Dagbladet!
It elaborates a little on our increased focus on our orphan drug designation and the perspectives and possibilities it gives.
Dorte X. Gram / Elna Lembrér Åström / Gustav Hanghøj Gram
Läs (in Swedish) här
(15 April-2023)
Presentation from the 15th annual Lifescience Capital Markets day in Stockholm hosted by Stockholm Corporate Finance and Financial Hearings. CEO, Dorte X. Gram gives a brief update on the company, status and thoughts/plans for the next foreseeable future.
Please, find the link to the video (in English) here
(10 March-2023)
Bokslutskommuniké 1 JANUARI – 31 DECEMBER 2022
Läs rapporten PDF (in Swedish) här
(28-February-2022)
LSX Inv€$tival, London 13 November
Our team is pleased to be back in London for the LSX Inv€$tival day-conference. We look forward to update investors and potential pharma partners on our progress and plans and to discuss 1-to-1 on how our TRPV1 solution for treatment of obesity, diabetes and CVD aligns attractively with the obesity market and its new treatment
Please Follow the event here
LSX Nordic, Copenhagen 10-11 October
Our team is delighted to participate in LSX Nordic in Copenhagen. We are pleased to have a presentation slot on Wednesday at 11:15am and look forward to meaningful partnering and financing discussions. We welcome investors for 1-to-1 meetings at the venue to discuss our TRPV1 solution for treatment of obesity, diabetes, CVD & more
Please Follow the event here
Our CEO Dorte X. Gram will be participating in the Annual meeting of the European Association for the Study of Diabetes and will be available for meetings.
Please request meeting at info@pilapharma.com
Our CEO Dorte X. Gram will be presenting a status update to Swedish investors.
Streaming available here
Our CEO Dorte X. Gram will be presenting a status update to Danish investors (no streaming)
Sign up to participate on-site here
ADA AMERICAN DIABETES ASSOCIATION CONVENTION – SAN DIEGO 2023
Our CEO Dorte X. Gram will be attending the ADA and is available for meetings regarding our diabetes project.
SAN DIEGO, CA / CONVENTION CENTER | JUNE 23-26, 2023
BIO INTERNATIONAL CONVENTION – BOSTON 2023
Our CEO Dorte X. Gram will be attending BIO and is available for meetings regarding both our diabetes and orphan (erythromelalgia) projects
June 5-8, 2023・Boston Convention & Exhibition Center – Boston, MA
2023 REDEYE THEME DAY: DIABETES
Our CEO Dorte X. Gram will be presenting an update on our diabetes project
The presentation can be viewed online on 24 May here
Meet our CEO, Dorte X. Gram at:
Bio€quity Europe 2023, Dublin
Please, Register here
(03 May-2023)
Anglonordic Life Science Conference 2023
19-20 april, London, UK here
(06 April-2023)
NORDIC RARE DISEASE SUMMIT 2023
17 april, Stockholm, Sweden here
(06 April-2023)
We’re delighted to be in Stockholm this Thursday, March 9th, where our CEO Dorte X. Gram will present at the 15th Lifescience Capital Marketsday hosted by Stockholm Corporate Finance and FinancialHearings!
Dorte X. Gram will take the stage at 10:45!
Sign up in the link below for live or digital participation: https://lnkd.in/eZrgfJvW
(07-March-2023)
Dorte X. Gram, CEO presenterar på Redeye Investor AW – Göteborg
Please, find the link to the video (in English) here
(10-November-2022)
INBJUDAN TILL TECKNING AV AKTIER I PILA PHARMA AB (PUBL)
Läs Memorandum PDF (in Swedish) här
(02-November-2022)
Delårsrapport 1 JULI – 30 SEPTEMBER 2022
Läs rapporten PDF (in Swedish) här
(26-October-2022)
Delårsrapport 1 april – 30 juni 2022
Läs rapporten PDF (in Swedish) här
(26-August-2022)
We’re delighted to be back at the wonderful Børsen with Dansk Erhverv, Medicon Valley Alliance Øresundsinstituttet next Monday, May 30th to discuss regional success, collaboration, challenges and more! 🟠
(23-May-2022)
Dorte’s presentation from last weeks visit to Redeye Investor forum is now online. Please find a link below for a brief update and a good Q&A 
Please, find the link to the video (in English) here
(16-May-2022)
Late last week Redeye had a brief interview with our CEO, Dorte X. Gram regarding the last quarterly report and recent significant changes and developments in Pila.
Please, find the link to the video (in English) here
(03-May-2022)
Delårsrapport 1 januari – 31 mars 2022
Läs rapporten PDF (in Swedish) här
(26-April-2022)
Läs (in Swedish) här
(05-April-2022)
Årsredovisning för 2021
Läs rapporten PDF (in Swedish) här
(23-March-2022)
The recording of our CEO Dorte X. Gram’s presentation (in Swedish) from Aktiespararna is now live.
Please, find the link to the video (in Swedish) here
(15-March-2022)
(05-March-2022)
(04-March-2022)
Please, find the link to the video (in English) here
(02-March-2022)
PILA PHARMA bokslutskommuniké för 1 januari – 31 december 2021
Läs rapporten PDF (in Swedish) här
(18-February-2022)
Please, read the article (in Swedish) here
(07-February-2022)
(17-January-2022)
(17-December-2021)
(17-December-2021)
(10-December-2021)
(10-December-2021)
(08-December-2021)
(02-December-2021)
(01-December-2021)
Läs hela artikeln (in Swedish) här
(01-December-2021)
(23-November-2021)
(19-November-2021)
(19-November-2021)
(19-November-2021)
(05-November-2021)
(05-November-2021)
(02-November-2021)
Delårsrapport 1 juli – 30 september 2021
Läs läs rapporten PDF (in Swedish) här
(26-October-2021)
Yesterday, our CEO Dorte X. Gram presented our company at Aktiespararna.
Please find a link to the presentation here
(29-September-2021)
Our COO, Lars Bukhave Rasmussen (and possibly som other PILAs), will be attending “The Future of Swedish & Danish Life Science” meeting in Lund, Sweden September 2nd 2021.
Read more (in English) here
(26-August-2021)
Read more (in Danish) here
(23-July-2021)
PILA PHARMA AB is off 
Our listing on Nasdaq was one ‘once in a life-time’ event and our CEO want to thank everybody involved in making it happen.
(15-July-2021)
Today, at 9 am CET the PILA PHARMA team will be ringing the bell – follow us live here
(15-July-2021)
Very pleased that Nasdaq last week gave PILA PHARMA AB the final approval for the list. We look forward to ‘first trading day’ on Thursday 15 July 2021.
For your information, our ‘ticker’ ‘PILA’
Read more (in English) here
(08-July-2021)
On 16 June, Børsen published this well-written article on PILA PHARMA AB by Kevin Grønnemann commented by Senior Equity Analyst Søren Løntoft Hansen at Sydbank. I was pleased to see, that Søren, believe ‘it can be done’! With Sørens permission, I’m pleased to share an English summary of his statements: “Even though it will not be an easy task, I think that a compound that effectively lowers blood glucose, has a good safety profile and perhaps addresses some of the co-morbidities of diabetes as cardio-vascular disease, can be made. If, on top, the compound can be marketed at lower cost, then I actually believe it has potential!”. (in Danish) here
(16 june 2021)
We are so incredibly honoured to share that the American Diabetes Association(ADA) is featuring PILA PHARMA AB in the Thought Leadership Film Series, a part of ADA’s 81st Scientific Sessions program in June 2021, starting today.
In the invitation letter, it was written: We are interested in profiling Pila’s pioneering research and development in the science surrounding TPRV1 inhibition, and how regulation of this mechanism has tremendous potential to be exploited for the treatment of diabetes. The pandemic has triggered a diabetes crisis of another sort, having multiplied the complications associated with the disease and has left diabetics more vulnerable than ever before. The pandemic has further underscored the dire need for innovative approaches that go beyond the conventional realms of the diabetes field, and therefore facilitating this is the primary focus for ADA TV this year. There is substantial pre-clinical evidence indicating a role for TPRV1 in metabolic diseases, however this novel avenue has never really been pursued despite its potential. Given that Pila Pharma is one of the few organisations that is working in this innovative space, we believe that it has the potential to make an incredibly valuable addition to this year’s series, as many in the diabetes community could learn and benefit greatly from the story behind your work.”
What at great honour – it fuels us with energy and strength to overcome all challenges ahead in order to eventually provide our new type of diabetes treatment to people with diabetes in need there off!
Thank you so much to our scientific advisors Mark Evans and Jens Juul Holst for helping our CEO explain!
Watch the video in English here
(24 june 2021)
Affärsvärlden published their IPO-analysis (in Swedish) of PILA PHARMA AB. We note that they find our premoney valuation fair here
(23 june 2021)
Thank you to Millionærklubben and Pernille Enggaard for paying attention to us and for yesterdays radio-interview of our CEO. You can listen to it here (in Danish), time 19:09 to 37:5 here
(22 june 2021)
Pitching the PILA PHARMA AB investment case live for Aktiespararna
Watch the video where we explain what PILA PHARMA is about. (in Swedish) here
(21 june 2021)
Proud to be on the cover of todays LIFE SCIENCE appedix in Politiken (in Danish)
Science for Life – makes everyday life meaningful to me!
(18 june 2021)
“PILA PHARMA vill ta ett nytt grepp om diabetes”
Biostock feature article on PILA PHARMA (in Swedish) here
(18 june 2021)
Analyse the IPO Guide PILA PHARMA
Diabetes company with new treatment in sight.
Read the analysis (in Swedish) here
(21 june 2021)
“Hon går till börsen med framtidens diabetesläkemedel”
Article on PILA PHARMA AB out now on the Swedish online magazine Realtid (in Swedish)
(20 june 2021)
”PILA PHARMA AB med den tidligere Novo Nordisk-forsker Dorte X. Gram i spidsen er nu klar til at ringe med børsklokken på det svenske Nasdaq First North Growth Market i Stockholm.”
Feature article in the life science magazine MedWatch (in Danish) here
(16 june 2021)
”PILA PHARMA rustar bolaget inför en ny fas och accelererad utvecklingsresa”
Feature article in Dagens Industri appendix Invest Talks (in Swedish) here
(15 june 2021)
”Nu påbörjas resan mot framtidens diabetesläkemedel”
PILA PHARMA AB featured in an article on p. 19 in Dagens Industri appendix Hållbar Finans with focus on sustainable finance (in Swedish) here
(10 june 2021)
This publication about DANSK BIOTEK is distributed in Denmark with todays Berlingske.
Read about on page 12-13 and about my personal view on fundraising in Denmark vs Sweden on page 20! (in Danish) here
NY PILLE SKAL FORBEDRE LIVET FOR MILLIONER AF TYPE 2-DIABETIKERE (in Danish) here
NÅR BIOTEK-SUCCES KRÆVER DET BEDSTE FRA BÅDE DANMARK OG SVERIGE (in Danish) here
(19-May-2021)
We’ve been interviewed about our background and our intentions to list PILA PHARMA AB later this year.
Please, read the article by Biostock (in Swedish) here
(23-Apr-2021)
Video interview (in Swedish) with CEO Dorte X. Gram by ‘Invest Talks’
Watch the interview in Swedish here
(12-Mar-2021)
Development of a novel drug to treat diabetes.
Investor presentation by CEO Dorte X. Gram at the BioStock Life Science Summit 2020, Lund, Sweden.
Watch the presentation in English here
(17-Nov-2020)
The Malmö-based company Pila Pharma, which has a drug candidate for type 2 diabetes, will be listed on one of the Swedish stock exchanges in the second quarter of next year.
Read the article in Swedish here
(17-Nov-2020)
Pila Pharma has scheduled its arrival on the Swedish stock market for May next year with the goal of fetching SEK 50m for developing the firm’s diabetes tablet leading up to phase III.
An interview with CEO Dorte X. Gram by Medwatch, Denmark.
Read the article in English here
Read the article in Danish here
(17-Nov-2020)
Our Opinion and Concept Paper on the role of TRPV1 in diabetes published in Trends in Molecular Medicine.
Read the paper here
(November 2017)
Novo-forsker gjorde ph.d.-projekt til biotekselskab og forbereder nu fase 2-studie.
An interview with CEO Dorte X. Gram by Medwatch, Denmark.
Read the article in Danish here
(1 January 2019)
Om jag har rätt kan detta bli gigantisk.
An interview with CEO Dorte X. Gram by BioStock, Sweden.
Read the article in Swedish here
PILA PHARMA är klar med uppstartsfasen och flyttar ut från inkubatorn.
An interview with CEO Dorte X. Gram published by Medeon, Sweden.
Read the article in Swedish here
Nytt piller skal göra livet lättare för diabetiker – svensk bolag vill förändra sjukvården.
An interview with CEO Dorte X. Gram published in Veckans Affärer, Sweden.
Winning prize to PILA PHARMA at the Almi Invest pitch competition 2016, sponsored by Veckans Affärer.
Check out the resulting article here
Uppstickaren som vill ta plats i läkemedelsindustrin.
An interview with CEO Dorte X. Gram published in ‘DI Almedalen, Distributed with Dagens Industri, Sweden.
Read the article in Swedish here
We are proud to be on the cover of the June 2017 issue of Affärslivet Norden, Medicine and Science magazine that focuses on innovation.
The magazine was distributed with Svenska Dagbladet.
Read the article in Swedish here
“Min uppfinning kom och hämtade tillbaka mig”
Dr. Dorte X. Gram, CEO of PILA PHARMA was interviewed by Sydsvenskan, Sweden.
Read the article in Swedish here
After ten years of diabetes R&D at Novo Nordisk, Dorte X. Gram took her findings and work further to start something on her own. As founder and CEO of PILA PHARMA she hopes to bring a new oral anti-diabetic agent to the market.
Read the article here
Development of a novel drug to treat diabetes.
Investor presentation by CEO Dorte X. Gram at the BioStock Life Science Summit 2018, Lund, Sweden.
Watch the presentation in English here
(25-Oct-2018)
We’re very pleased to share PILA PHARMA AB‘s new Youtube channel.
The first film shows a guest lecture at Prague University in September 2017 where CEO Dorte X. Gram talked to students about starting up a biotech company.
Watch the video here
(04-Sep-2017)
At BioEurope Spring in Stockholm in April 2016 Dr. Dorte X. Gram, CEO of PILA PHARMA was interviewed by the organizers about the current status and our plans going forward.
Please find the links below:
partnering360.com
(08-Apr-2016)
PILA PHARMA yesterday won the title “Årets pitchare 2016” at the ALMI Invest Seed Day in Stockholm, Sweden!
The 1-min pitch competition was held amongst 17 selected out of ALMI Invests 400 portfolio companies.
(06-Dec-2016)
In order to maximise the chance of getting to the final, I chose to do an alternative type of pitch to describe the ALMI-PILA history as well as the content of the project (indirectly).
At the final I did ‘the usual stuff’ with market size, potential return of investment and potential exit value (potentially in the unicorn league).
I’m very proud that the audience yesterday selected me and PILA PHARMA as winner of the title ‘Årets pitchare 2016’ at the ALMI Invest Seed Day!
ALTERNATIVE PITCH by PILA PHARMA:
Tack Sverige för ett fantastisk inkubator och innovations system!
Tack Malmö för ett häftigt uppstarts och tillväxt miljö!
— Forza Malmö, eller hur, Per?
Tack Per Antonsson, ALMI Invest Syd, för att du inte tröttnade på min mejl-storm om min teori!
Tack Universum för att Per hade förmåga att förstå teorin och att inse hur STORT det skulle kunna bli om man kan bota diabetes genom att blokera chili-receptorn!
Tack ALMI Invest för att ni vågade satsa på min kostnads-effektiva plan om snabb klinisk bevis för min diabetes tablet – och sen exit!
Tack befintliga och kommande investerare för att ni inte bara vil tjäna masser med pengar men också vil göra något bra för samhället och vara med om att slå ihjäl det stora diabetes-monster!
Tack!
Past meetings
78th Scientific Sessions
Orlando, Florida
June 22 – 26, 2018
3rd Biotech Hanse
Stockholm, Sweden
June 14, 2018
The Future of Swedish & Danish Life Science
Lund, Sweden
March 22, 2018
Diabetes Samverkan Sverige
Malmö, Sweden
March 22, 2018
BIO-EUROPE SPRING
Amsterdam, The Netherlands
March 12-14, 2018
BOSTON BIOTECH CONFERENCE
EUROPE CEO
Amsterdam, The Netherlands
March 11, 2018
French-Swedish Life Science Day 2017
Paris, France
December 14, 2017
Nordea Markets
Copenhagen, Denmark
November 20, 2017
Nordea Markets
Medicon Valley Alliance
Annual Meeting 2017 – Health, Wealth And World Class
Copenhagen, Denmark
November 10, 2017
Medicon Valley Alliance
BIO-Europe
23RD Annual International
Partnering Conference
Berlin, Germany
November 6–8, 2017
Bio-Europe
Nordic Life Science Days
Malmö, Sweden — Copenhagen, Denmark
September 12-14, 2017
nlsdays.com
European Association for the Study of Diabetes
Lisboa, Portugal
September 11-15, 2017
easd.org
Dr. Dorte X. Gram has accepted to give a talk entitled: ‘If I’m right, this could be a really big thing! – daring to challenge status-quo in diabetes treatment’
Prague Summer School – Advances in Drug Discovery
September 4-8, 2017
Prague, Czech Republic
praguesummerschool.cz
San Diego, CA
June 9-13, 2017
the American Diabetes Association’s
77th Scientific Sessions
professional.diabetes.org
San Diego, CA
June 19-22, 2017
The BIO International Convention
convention.bio.org
BioEurope Spring 2017
March 20–22, 2017
CCIB Convention Centre, Barcelona Spain
ebdgroup.com
Next Big Thing, Financial hearing, 2016
Live webcast Next Big Thing from Moderna Museet, Stockholm, Sweden.
December 2nd 2016, 13.00 (UTC/GMT +1 hour)
Almi Invest Seed Day
5 december 2016, Stockholm, Sweden.
PILA PHARMA’s CEO, Dr. Dorte Gram was invited to participate in a company pitch competition amongst 15 of ALMI Invest’s 400 portfolio companies.
Eventregistrering.se
BIO-Europe.
November 7–9, 2016, Cologne, Germany.
- Lifestyle diseases and longevity
PILA PHARMA’s CEO, Dr. Dorte Gram was invited to participate as a key speaker in a panel discussion in:
Day: Monday
Date: November 7, 2016
Time: 16:00
Room: 2 on level 2 - PILA PHARMA’s company presentation:
Day: Tuesday
Date: November 8, 2016
Time: 17:15
Room: Rheinsaal 4 on level 2
BIO-Europe.com
French-Swedish Life Science Day 2016.
October 20, 2016 at the Swedish Embassy, 17 Rue Barbet de Jouy, in Paris.
French-Swedish Life Science Day.eu
Nordic Life Science Days is the largest Nordic partnering conference for the global Life Science industry.
September 14-15, 2016, Stockholm, Sweden.
Nordic Life Science Days.com
Boehringer Partnering Day.
September 13, 2016, Stockholm, Sweden.
bipartnering.com
52nd EASD (European Association for the Study of Diabetes) Annual Meeting.
September 12-16, 2016, Munich, Germany.
easd.org
Anglo-Nordic Lifescience Conference XIII
May 19, 2016 London, United Kingdom
anglonordiclifescience.com
Dansk Bioteks Årsmøde
May 4, 2016 Copenhagen, Denmark
danskbiotek.dk
Bio-Europe Spring 2016
April 4-6 2016, Stockholm, Sweden
ebdgroup.com
10th Swiss-Scandinavian Bio-Business Seminar
February 10, 2016 at SIX Stock Exchange building in Zurich, Switzerland
b2match.eu